Harvest Portfolios Group Inc. Has $61.90 Million Stock Position in Medtronic PLC $MDT

Harvest Portfolios Group Inc. lessened its stake in Medtronic PLC (NYSE:MDT) by 2.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 649,942 shares of the medical technology company’s stock after selling 16,221 shares during the quarter. Medtronic makes up approximately 1.1% of Harvest Portfolios Group Inc.’s investment portfolio, making the stock its 22nd largest position. Harvest Portfolios Group Inc.’s holdings in Medtronic were worth $61,900,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Delos Wealth Advisors LLC acquired a new stake in Medtronic in the second quarter valued at $27,000. Corundum Trust Company INC bought a new stake in shares of Medtronic in the 3rd quarter valued at about $27,000. Valley Wealth Managers Inc. bought a new position in Medtronic during the third quarter worth about $29,000. Steigerwald Gordon & Koch Inc. acquired a new position in Medtronic during the third quarter worth approximately $33,000. Finally, Tripletail Wealth Management LLC bought a new stake in Medtronic in the third quarter valued at approximately $34,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Positive clinical readout for Altaviva tibial neuromodulation for urinary incontinence — could support future revenue and adoption in restorative/urogynecologic portfolio. Medtronic reports positive findings for Altaviva tibial neuromod
• Positive Sentiment: Analyst coverage remains constructive: consensus “Moderate Buy” and several buy/overweight ratings and raised price targets underpin the stock’s positive bias; company also maintains a steady dividend (annualized ~$2.84, ~2.9% yield). Medtronic PLC Given Average Recommendation of “Moderate Buy” by Analysts
• Neutral Sentiment: Mixed recent share performance and valuation commentary: short-term momentum is cooling (negative returns over recent weeks/months) though 1‑year TSR remains positive — investors are watching whether earnings/guidance sustain the multiple. Assessing Medtronic (MDT) Valuation After Mixed Recent Share Performance
• Neutral Sentiment: Analysis shows MDT has underperformed the S&P 500 over the past year, which may cap sentiment despite company fundamentals — useful context for relative-performance and ETF/sector flows. How Medtronic Impacted The Healthcare Sector on The S&P 500 Chart
• Negative Sentiment: Large insider sale: EVP Harry Skip Kiil sold 52,524 shares (~$5.13M at ~$97.71) and materially reduced his position — raises some investor caution though insiders may sell for personal/liquidity reasons rather than company outlook. Medtronic EVP Harry Skip Kiil Sells 52,524 Shares

Analyst Ratings Changes

MDT has been the subject of several research analyst reports. Needham & Company LLC reduced their target price on Medtronic from $121.00 to $120.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. Morgan Stanley upped their price objective on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Barclays restated an “overweight” rating and set a $118.00 target price on shares of Medtronic in a research note on Wednesday, February 18th. Finally, Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $110.84.

Medtronic Stock Up 0.6%

Shares of MDT opened at $97.60 on Friday. The company has a current ratio of 2.54, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The firm’s 50 day moving average is $98.93 and its 200-day moving average is $96.86. The stock has a market capitalization of $125.31 billion, a PE ratio of 27.19, a P/E/G ratio of 2.44 and a beta of 0.71.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is 79.11%.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.26% of the stock is owned by corporate insiders.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).